[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339273-105":59,"doc-detail-339273-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","selective-targeting-of-regulated-rhabdomyosarcoma-cells-by-trinuclear-rutheniumii-arene-complexes","Selective Targeting of Regulated Rhabdomyosarcoma Cells by Trinuclear Ruthenium(II)-Arene Complexes","","The study reports benzimidazole-based trinuclear ruthenium(II)-arene complexes (1–3) designed to selectively target rhabdomyosarcoma, a rare cancer. Cytotoxic testing across an eight-cancer cell line panel showed enhanced, selective effects against RMS cells, with complex 1 delivering superior short- and long-term killing and improved selectivity over cisplatin. Complex 1 also suppresses metastatic cell migration and preserves higher activity in a 3D multicellular spheroid model compared with cisplatin. Mechanistic analysis indicates genomic DNA damage, autophagy induction, and activation of intrinsic and extrinsic apoptotic pathways.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/selective-targeting-of-regulated-rhabdomyosarcoma-cells-by-trinuclear-rutheniumii-arene-complexes/339273/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/selective-targeting-of-regulated-rhabdomyosarcoma-cells-by-trinuclear-rutheniumii-arene-complexes/339273.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main purpose of the benzimidazole-based trinuclear ruthenium(II)-arene complexes (1–3)?","Question",{"text":113,"@type":114},"They are developed to selectively target rhabdomyosarcoma cells and evaluate whether their cytotoxicity is enhanced specifically for RMS compared with existing treatments.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does complex 1 perform relative to cisplatin?",{"text":118,"@type":114},"Complex 1 shows superior short- and long-term cytotoxicity in RMS cell lines and enhanced selectivity versus cisplatin, including stronger performance in a 3D multicellular spheroid model.",{"name":120,"@type":111,"acceptedAnswer":121},"Which biological mechanisms are implicated in the action of complex 1 against RMS cells?",{"text":122,"@type":114},"Complex 1 induces genomic DNA damage, triggers autophagy, and activates intrinsic and extrinsic apoptotic pathways.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},339273,1790194820,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","This article is licensed under CC-BY 4.0   \n[pubs.acs.org/jmc](pubs.acs.org/jmc)  Article   \nSelective Targeting of Regulated Rhabdomyosarcoma Cells by Trinuclear Ruthenium(II)−Arene Complexes  \nAthi Welsh, Karabo Serala, Sharon Prince, and Gregory S. Smith *  \n Cite This: J. Med. Chem. 2024, 67, 6673−6686  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: The use of benzimidazole-based trinuclear ruthenium-(II)−arene complexes ( 1−3) to selectively target the rare cancer rhabdomyosarcoma is reported. Preliminary cytotoxic evaluations of the ruthenium complexes in an eight-cancer cell line panel revealed enhanced, selective cytotoxicity toward rhabdomyosarcoma cells (RMS). The trinuclear complex 1 was noted to show superior shortand long-term cytotoxicity in RMS cell lines and enhanced selectivity relative to cisplatin. Remarkably, 1 inhibits the migration of metastatic RMS cells and maintains superior activity in a 3D multicellular spheroid model in comparison to that of the clinically used cisplatin. Mechanistic insights reveal that 1 effectively induces genomic DNA damage, initiates autophagy, and prompts the intrinsic and extrinsic apoptotic pathways in RMS cells. To the best of our knowledge, 1 is the first trinuclear ruthenium(II) arene complex to selectively kill RMS cells in 2D and 3D cell cultures.  \n1. INTRODUCTION  \nDespite significant research efforts and investment over the past 20 years, cancer remains a leading cause of death with over 19.3 million new cases and 10 million deaths reported globally in 2020.1,2 One of the most commonly used treatment modalities involves the use of chemotherapeutics, with platinum metallodrugs cisplatin, carboplatin, and oxaliplatin demonstrating global clinical success and being frequently utilized as frontline metal-based therapeutics with FDA approval.3 At least half of all cancer patients are estimated to receive these nascent platinum-based chemotherapies at some point during their treatment regimens, despite the unfavorable side effects that are frequently linked to their use (such asnephrotoxicity, myelosuppression, and chemotherapy-induced nausea and vomiting), as well as the growing number of platinum-resistant cancers.4−8 To circumvent these detrimental attributes associated with the archetypical platinum metallodrugs, several alternative strategies have been explored including the development of metallodrugs with alternate platinum-group metals (PGMs), the development of multinuclear complexes, and more recently, the investigation of  \nheteronuclear metal complexes and nanotechnology.9−13  \nRuthenium is currently at the forefront of PGM-based metallodrug discovery. This is due to the favorable biological characteristics associated with ruthenium-containing complexes including selective uptake, enhanced selectivity relative to platinum metallodrugs, and the various oxidation states that are accessible in vitro.14, 15 Moreover, there are several reports of ruthenium-based metal complexes that exert cytotoxic effects through a range of mechanisms of action including  \napoptosis induction, glucose metabolism reprogramming, HER-2 repression, necroptosis induction by targeting topoisomerases I and II, and induction of redox imbalance, all of which provide an impetus for the development of rutheniumbased cytotoxic agents. 16−21  \nPolymetallic complexes are complexes that comprise of more than one metal center. Generally, polymetallic complexes have been reported to show enhanced cytotoxicity and novel mechanisms of action relative to their mononuclear counterparts, which provides further incentive to the investigation of these types of complexes as anticancer agents.22−25 Encouraged by the discovery of the trinuclear complex [transdiamminechloroplatinum(II)] [μ-trans-diamminebis-(hexanediamine)platinum(II)] nitrate (BBR3464) as the first polynuclear pla","cbCaifI3KCCgqkrx","https://ap.wps.com/l/cbCaifI3KCCgqkrx","pdf",6404955,"English","# Abstract\n## Introduction","[{\"question\":\"What is the main purpose of the benzimidazole-based trinuclear ruthenium(II)-arene complexes (1–3)?\",\"answer\":\"They are developed to selectively target rhabdomyosarcoma cells and evaluate whether their cytotoxicity is enhanced specifically for RMS compared with existing treatments.\"},{\"question\":\"How does complex 1 perform relative to cisplatin?\",\"answer\":\"Complex 1 shows superior short- and long-term cytotoxicity in RMS cell lines and enhanced selectivity versus cisplatin, including stronger performance in a 3D multicellular spheroid model.\"},{\"question\":\"Which biological mechanisms are implicated in the action of complex 1 against RMS cells?\",\"answer\":\"Complex 1 induces genomic DNA damage, triggers autophagy, and activates intrinsic and extrinsic apoptotic pathways.\"}]","Selective Targeting of Regulated Rhabdomyosarcoma Cells by Trinuclear Ruthenium(II)-Arene Complexes | PDF",1790029114,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c007d5ed8a49df3504f7bf4a310c77a5.webp",983,1296,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e39c51cd628835a1c27938d457140109.webp",982,1295,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31a15ef71c974194a989e096babb2eb3.webp",981,1293,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8db27d943e223ec67daaf096c9174b4.webp",980,1292]